Combination Therapies For Challenging Chronic Conditions - Joel Latham - CEO, #Incannex Healthcare Inc. joins me on Progress, Potential, And Possibilities #ObstructiveSleepApnea #RheumatoidArthritis #GeneralizedAnxietyDisorder #Cannabidiol #Psilocybin
www.youtube.com/watch?v=OOux...

Incannex stock surges after positive sleep apnea trial results Investing.com -- Incannex Healthcare Inc. (NASDAQ:IXHL) stock jumped 10% Friday following the release of positive Phase 2 trial results for its obstructive sleep apnea (OSA) treatment, IHL-42X. The clinical-stage pharmaceutical company reported compelling efficacy data from its RePOSA Phase 2 trial, with patient exit interviews revealing that 57.6% of participants experienced perceived improvements in their OSA condition. Among those reporting benefits, 89.5% described the changes as meaningful to their daily lives. The trial demonstrated statistically significant improvements across multiple key endpoints. Patients receiving IHL-42X showed significant reductions in Apnoea-Hypopnoea Index (AHI) compared to placebo, with 41.2% of high-dose recipients achieving greater than 30% reduction in AHI. Some patients experienced AHI reductions of up to 83%. "Our recent Phase 2 results for IHL-42X exceeded expectations. In some patients, we observed reductions in AHI of up to 83%, which is an extraordinary outcome and a powerful signal of the drug’s potential," said Joel Latham, President and CEO of Incannex. The treatment also demonstrated an excellent safety profile with no serious adverse events reported during the treatment period. Most treatment-emergent adverse effects were mild or moderate. Patients reported improvements in sleep quality, reduced daytime sleepiness, fewer cognitive disturbances, and greater ease in completing daily responsibilities. Unlike many sleep medications, IHL-42X did not reduce REM sleep, an important stage for memory consolidation and brain health. The company remains well-capitalized to continue advancing its clinical programs while exploring strategic options to deliver long-term value to shareholders. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Incannex #StockMarket #Investing #SleepApnea #TrialResults

Incannex stock soars after positive Phase 2 results for sleep apnea drug Investing.com -- Incannex Healthcare Inc. (NASDAQ:IXHL) stock rose 10% following the announcement of positive topline results from its Phase 2 clinical trial for IHL-42X, a novel oral drug candidate for obstructive sleep apnea (OSA). The company reported that its RePOSA trial demonstrated statistically significant improvements across multiple key endpoints. Most notably, IHL-42X reduced the Apnoea-Hypopnoea Index (AHI) by up to 83% from baseline compared to placebo, with both low and high-dose groups showing significant improvements. The trial enrolled 121 adult participants with moderate to severe OSA who received either a high dose, low dose, or placebo version of IHL-42X for 28 days. The drug also showed improvements in oxygen desaturation, patient-reported outcomes measuring sleep quality, and reduced daytime fatigue. IHL-42X demonstrated what the company described as an "outstanding safety profile" with no serious adverse events reported during the treatment period. Treatment-emergent adverse effects were infrequent and primarily mild to moderate in severity. "We are extremely pleased with the RePOSA trial results. The combination of statistically significant improvements across multiple endpoints and an outstanding safety profile positions IHL-42X as one of the most compelling drug candidates in the global race to bring a pharmaceutical treatment for OSA to market," said Joel Latham, CEO and President of Incannex. The company is now preparing for an End-of-Phase 2 meeting with the FDA to discuss the path forward for Phase 3 trials and regulatory strategy. Incannex noted that OSA affects over 900 million people globally with no approved oral pharmaceutical treatments currently available. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Before you buy stock in IXHL, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is IXHL one of them?

Click Subscribe #Incannex #Healthcare #Investing #StockMarket #SleepApnea

Mid-day market movers!
#Veru_Pharma ( #VERU) Gains 17% on Positive Safety Data for Enobosarm + Semaglutide Combo
#Incannex ( #IXHL) Drops 15% Despite Strategic Warrant Cancellation
prismmarketview.com/prism-mid-da...